Drug shortages plague Europe due to production issues and logistics; Italy sees record cases while other nations implement varied responses.
🔗 Read the article on ilsole24ore.com
[This is an automatically generated summary, for reference only]
Drug shortages are a widespread issue stemming from production problems, scarcity of active ingredients, concentrated Asian manufacturing, and logistical frailties, compounded by fragmented information sharing. In Italy, drug shortages reached record levels in August, affecting thousands of medications including antibiotics and cancer drugs; oncologists report difficulties sourcing essential molecules, leading to treatment delays for 97% of healthcare professionals managing patients awaiting medicine. The Italian government plans supply security measures, but the sustainability of generic drugs is crucial for national health security. A new pharmaceutical legislation aims to reform the entire supply chain, focusing on securing supplies and promoting generics. Internationally, France still faces high levels of therapeutic drug shortages despite a slight decrease in 2024, with concerns over antidepressant availability; the French government has implemented measures like mandatory stockpiling. Spain is experiencing severe shortages of antidepressants, with Anafranil being the most affected, while ADHD medications also face issues. Bulgaria suffers from chronic shortages due to its fragile market and low prices, leading patients to seek medication abroad despite export bans on critical drugs. Austria demonstrates a more effective strategy against shortages through measures like mandatory four-month stockpiles for essential medicines and public restriction registries, which helps maintain therapeutic security.
